BACKGROUND: The pulmonary vasculopathy in pulmonary arterial hypertension (PAH) results in increased resistance to pulmonary blood flow, limiting the cardiac output required for the increased O(2) demands of exercise. AIMS: We sought to determine the physiologic basis for clinical improvement in PAH patients receivingsildenafil, hypothesizing that the key mechanisms of improvement are improved blood flow and ventilatory efficiency, leading to improved exercise capacity and O(2) pulse over time. METHODS: We studied 28 PAH patients with (n=14) and without (n=14) sildenafil treatment. All received warfarin and diuretic therapy, and 13/14 sildenafil-treated patients were already receiving specific PAH drugs. Cardiopulmonary exercise testing was performed before and after sildenafil. RESULTS:Peak VO2 , peak O(2) pulse, V E/CO2 and PETCO2, were 0.84+/-0.1 L/min, 6.1+/-0.7 mL beat(- 1), 49+/-2 and 26+/-1.5 mm Hg, and improved after adding sildenafil to 0.91+/-0.1 L/min, 6.8+/-0.8 mL beat(- 1), 43+/-2, and 30+/-1.9, respectively, whereas control patients worsened (p=0.012, 0.008, 0.008 and 0.0002, treated vs. controls, respectively). CONCLUSIONS:Sildenafil improves PETCO2, V E/V CO(2), peak O2 pulse and peak VO2 during exercise compared to controls. A prospective, placebo-controlled study is needed to validate these findings.
RCT Entities:
BACKGROUND: The pulmonary vasculopathy in pulmonary arterial hypertension (PAH) results in increased resistance to pulmonary blood flow, limiting the cardiac output required for the increased O(2) demands of exercise. AIMS: We sought to determine the physiologic basis for clinical improvement in PAH patients receiving sildenafil, hypothesizing that the key mechanisms of improvement are improved blood flow and ventilatory efficiency, leading to improved exercise capacity and O(2) pulse over time. METHODS: We studied 28 PAH patients with (n=14) and without (n=14) sildenafil treatment. All received warfarin and diuretic therapy, and 13/14 sildenafil-treated patients were already receiving specific PAH drugs. Cardiopulmonary exercise testing was performed before and after sildenafil. RESULTS: Peak VO2 , peak O(2) pulse, V E/CO2 and PETCO2, were 0.84+/-0.1 L/min, 6.1+/-0.7 mL beat(- 1), 49+/-2 and 26+/-1.5 mm Hg, and improved after adding sildenafil to 0.91+/-0.1 L/min, 6.8+/-0.8 mL beat(- 1), 43+/-2, and 30+/-1.9, respectively, whereas control patients worsened (p=0.012, 0.008, 0.008 and 0.0002, treated vs. controls, respectively). CONCLUSIONS:Sildenafil improves PETCO2, V E/V CO(2), peak O2 pulse and peak VO2 during exercise compared to controls. A prospective, placebo-controlled study is needed to validate these findings.
Authors: S A van Wolferen; A Boonstra; J T Marcus; K M J Marques; J G F Bronzwaer; P E Postmus; A Vonk-Noordegraaf Journal: Heart Date: 2006-12 Impact factor: 5.994
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: K Lunze; N Gilbert; S Mebus; O Miera; W Fehske; F Uhlemann; E G Mühler; P Ewert; P E Lange; F Berger; I Schulze-Neick Journal: Eur J Clin Invest Date: 2006-09 Impact factor: 4.686
Authors: S C Mathai; R E Girgis; M R Fisher; H C Champion; T Housten-Harris; A Zaiman; P M Hassoun Journal: Eur Respir J Date: 2006-11-01 Impact factor: 16.671
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie Journal: Expert Rev Respir Med Date: 2011-04 Impact factor: 3.772
Authors: Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers Journal: Circulation Date: 2012-09-05 Impact factor: 29.690
Authors: Herman Groepenhoff; Anton Vonk-Noordegraaf; Mariëlle C van de Veerdonk; Anco Boonstra; Nico Westerhof; Harm J Bogaard Journal: PLoS One Date: 2013-09-05 Impact factor: 3.240